Search results for "FDA update"


 
Results 41 - 50 of about 88 for "FDA update".
Sort by: Relevance | Newest | Oldest

FDA clears marketing of mobile app for automated insulin dosing in type 1 diabetes

The prescription-only mobile application is intended for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons ages 6 years and older.
https://diabetes.acponline.org/archives/2023/02/10/6.htm
10 Feb 2023

FDA authorizes marketing of first interoperable, automated insulin dosing controller

The device automatically adjusts insulin delivery to a person with diabetes by connecting to an alternate controller-enabled insulin pump and integrated continuous glucose monitor.
https://diabetes.acponline.org/archives/2020/01/10/6.htm
10 Jan 2020

Nearly 1.5 million insulin syringes recalled

Recalled syringes may have graduated markings that are printed incorrectly on the syringe barrel.
https://diabetes.acponline.org/archives/2021/07/09/8.htm
9 Jul 2021

Warning on risks of canagliflozin

The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density.
https://diabetes.acponline.org/archives/2015/10/09/7.htm
9 Oct 2015

Metformin recalled due to nitrosamine impurity

The recall includes two lots of metformin hydrochloride extended-release tablets USP (750 mg) manufactured in India and distributed in the U.S.
https://diabetes.acponline.org/archives/2021/07/09/9.htm
9 Jul 2021

FDA approves new heart failure indication for SGLT-2 inhibitor

Originally approved in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes, the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance) is now approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
https://diabetes.acponline.org/archives/2022/03/11/10.htm
11 Mar 2022

First noninjection treatment for severe hypoglycemia approved

The nasal powder is indicated for the emergency treatment of severe hypoglycemia in patients with diabetes ages 4 years and older.
https://diabetes.acponline.org/archives/2019/08/09/8.htm
9 Aug 2019

Glucagon recalled due to detaching needles

Six batches of GlucaGen HypoKit (glucagon [rDNA origin] for injection) were recalled due to the possibility of needle detachment, the FDA recently announced.
https://diabetes.acponline.org/archives/2016/09/16/8.htm
16 Sep 2016

SGLT2 inhibitors associated with ketoacidosis

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, may cause ketoacidosis, the FDA recently warned.
https://diabetes.acponline.org/archives/2015/06/12/8.htm
12 Jun 2015

Warning about serious genital infections in patients taking SGLT2 inhibitors

The FDA has identified 12 cases of necrotizing fasciitis of the perineum or Fournier's gangrene. All 12 patients were hospitalized and required surgery, and one died.
https://diabetes.acponline.org/archives/2018/09/14/8.htm
14 Sep 2018

Result Page: Prev   1   2   3   4   5   6   7   8   9   Next